In a move to boost U.S. manufacturing, Eli Lilly will construct a new pharmaceutical plant in Pennsylvania. The $3.5 billion facility will focus on producing injectable weight-loss medications, including the promising drug retatrutide. This investment is part of a larger strategy by the drugmaker to expand domestic production and fortify its supply chains amid rising demand for weight-loss treatments.

This marks Lilly's fourth new manufacturing site in the U.S. and is the largest investment by a life sciences company in Pennsylvania's history. The plant's construction is slated to begin in 2026, with operations starting in 2031. The project will create at least 850 jobs, according to Governor Josh Shapiro. The site was selected from over 300 applicants.

This expansion follows a trend of pharmaceutical companies investing heavily in U.S. manufacturing. President Trump's threats of import tariffs on pharmaceutical products have spurred these investments. Lilly, along with competitors like Novo Nordisk, are racing to meet the soaring demand for GLP-1 weight-loss drugs.

Investors should watch how this expansion impacts Lilly's production capacity and its ability to compete with rivals like Novo Nordisk. The company is also planning to launch a weight-loss pill in several countries. Approval in the U.S. will be a key driver for future revenue and market share.